Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort - ENS de Lyon - École normale supérieure de Lyon Accéder directement au contenu
Article Dans Une Revue Journal of The American Academy of Dermatology Année : 2019

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

1 Service de Dermatologie
2 LIRIC - Lille Inflammation Research International Center - U 995
3 Service de Dermatologie [AP-HP Hôpital Saint-Louis]
4 PC - Polyclinique Courlancy
5 Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination
6 Hôpital Saint Vincent de Paul de Lille
7 Université de Clermont-Ferrand
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 Service de dermatologie [Rouen]
10 Service de Dermatologie [Rouen]
11 Service de dermatologie
12 Département de dermatologie
13 Service de Dermatologie [CHU Caen]
14 CHU Caen
15 Service de Dermatologie [Rennes] = Dermatology [Rennes]
16 CHU Tenon [AP-HP]
17 CIMI - Centre d'Immunologie et des Maladies Infectieuses
18 Service de dermatologie [CHU d'Amiens-Picardie]
19 Département de dermatologie, CHU Angers
20 Service de Dermatologie et pathologies vasculaires [CH Argenteuil]
21 CEReSS - Centre d'études et de recherche sur les services de santé et la qualité de vie
22 CHR Metz-Thionville - Centre hospitalier régional Metz-Thionville
23 Service de Dermatologie [Nice]
24 Centre Hospitalier René Dubos [Pontoise]
25 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
26 UPJV - Université de Picardie Jules Verne
27 Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles
28 CHU Pitié-Salpêtrière [AP-HP]
29 Service de dermatologie [CHU Necker]
30 Centre Hospitalier Le Mans (CH Le Mans)
31 Hôpital d'Instruction des Armées Sainte Anne
32 Neurofibromatosis Clinic
33 Biothérapies des maladies génétiques et cancers
Laurent Misery
  • Fonction : Auteur
  • PersonId : 904669
Cécile Morice
  • Fonction : Auteur
Jean-Philippe Lacour
Sébastien Barbarot

Résumé

BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Fichier principal
Vignette du fichier
S0190962219303457.pdf (262.12 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02321685 , version 1 (26-10-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, et al.. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. Journal of The American Academy of Dermatology, 2019, 81 (1), pp.143-151. ⟨10.1016/j.jaad.2019.02.053⟩. ⟨hal-02321685⟩
332 Consultations
107 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More